Background: Hepatic dysfunction in the cancer Dept has a significant impact on patient

outcomes. The therapeutic application of Anthracycline antibiotics is limited by side–effects mainly chronic Cardiotoxicity, Myelosuppression,  and Hepatotoxicity.

Aim: To Analyse the risk of Hepatotoxicity in Breast cancer patients receiving Inj. Doxorubicin.
Subjects and Methods: The investigation was a prospective study that was conducted in cancer patients receiving Inj. Doxorubicin doses of 50 mg/m², and 75 mg/m² at a South Indian tertiary care hospital. Sample collection was done from pre–chemotherapy to 4^th cycle. SGPT, SGOT,
Direct Bilirubin and Total Bilirubin were assessed to determine Hepatotoxicity. Data were
analyzed using unpaired t test, Pearson correlation using GraphPad Prism version 5.00.
Results: Breast cancer patients comprised 37% (49/132) of the total female cancer patient
population, of which 46 patients with mean age of 46.61 (13.39) years were included and 30.4% (14/46) patients were developed hepatotoxicity. The mean (SD) of SGOT, SGPT, Direct
Bilirubin, Total Bilirubin in pre–chemotherapy cycle to fourth chemotherapy cycle were found to be 21.97 (5.798) U/L and 181.3 (103.6) U/L, 23.17 (6.237) U/L and 147.6 (90.9) U/L, 0.1351
(0.1186) mg/dL and 0.5445 (0.4587) mg/dL, 0.3094 (1.346) mg/dL and 2.7163 (1.898) mg/dL
simultaneously where P < 0.05 which were statistically significant.

Conclusion: There exist a strong correlation between the use of Inj. Doxorubicin and risk for

developing hepatotoxicity. The healthcare professionals dealing with breast cancer patients need to have awareness for hepatotoxicity with the use of Inj. Doxorubicin therapy.